Nektar Therapeutics (NKTR) Projected to Post Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is anticipated to issue its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.69) per share and revenue of $10.4390 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $72.07 on Wednesday. Nektar Therapeutics has a one year low of $6.45 and a one year high of $75.67. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -9.04 and a beta of 1.17. The company’s 50 day moving average price is $51.72 and its 200 day moving average price is $52.47.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NKTR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Citigroup began coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They issued a “buy” rating and a $102.00 target price on the stock. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Finally, Piper Sandler restated an “overweight” rating and issued a $105.00 price objective on shares of Nektar Therapeutics in a report on Monday, January 26th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $126.29.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the sale, the chief executive officer owned 75,489 shares of the company’s stock, valued at $5,510,697. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares in the company, valued at $761,697.18. This trade represents a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,470 shares of company stock valued at $181,955 in the last ninety days. Insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in shares of Nektar Therapeutics by 336.9% during the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Prosight Management LP acquired a new stake in shares of Nektar Therapeutics in the fourth quarter valued at approximately $23,450,000. Two Sigma Investments LP increased its holdings in shares of Nektar Therapeutics by 446.9% in the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after purchasing an additional 354,842 shares in the last quarter. Invesco Ltd. raised its position in Nektar Therapeutics by 106.3% in the 4th quarter. Invesco Ltd. now owns 468,159 shares of the biopharmaceutical company’s stock worth $19,794,000 after purchasing an additional 241,262 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Nektar Therapeutics by 30.0% in the 3rd quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock worth $53,978,000 after purchasing an additional 219,155 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Neutral Sentiment: Multiple plaintiff firms are soliciting clients and reminding investors about the lead‑plaintiff deadline (May 5, 2026), which amplifies attention and could consolidate large investor claims. Notices came from Rosen, Schall, Faruqi & Faruqi, Robbins and Grabar (investigations/solicitations).
  Rosen Law Firm Urges Nektar Therapeutics Stockholders to Contact the Firm
  Schall Law Firm Notice
  Faruqi & Faruqi Reminder
• Negative Sentiment: Pomerantz LLP has filed a securities class action in the U.S. District Court for the Northern District of California alleging violations of Sections 10(b) and 20(a) and Rule 10b‑5 on behalf of investors who bought NKTR during the stated class period. This is an active court filing that formalizes investor claims. Pomerantz Law Firm Announces the Filing…
• Negative Sentiment: Holzer & Holzer (and other alerts) allege that enrollment in Nektar’s REZOLVE‑AA trial “had not followed applicable instructions and protocol standards,” claiming that issues could materially undermine the trial’s integrity and prior company statements — a specific substantive allegation that increases litigation risk and potential regulatory scrutiny. Holzer & Holzer Investor Alert
• Negative Sentiment: Additional firms (Bernstein Liebhard, Gainey McKenna & Egleston and others) have issued investor alerts or announced filings—demonstrating multiple independent actions are underway. Multiple, concurrent filings increase potential damages exposure and prolong headline risk for NKTR. Bernstein Liebhard Investor Alert

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.